Opioid Prescribing to Adolescents in the United States From 2005 to 2016
| dc.contributor.author | Henke, Rachel Mosher | |
| dc.contributor.author | Tehrani, Ali Bonakdar | |
| dc.contributor.author | Ali, Mir M. | |
| dc.contributor.author | Mutter, Ryan | |
| dc.contributor.author | Mazer-Amirshahi, Maryann | |
| dc.contributor.author | O'Brien, Peggy L. | |
| dc.contributor.author | Mark, Tami L. | |
| dc.date.accessioned | 2021-07-09T21:20:49Z | |
| dc.date.available | 2021-07-09T21:20:49Z | |
| dc.date.issued | 2018-07-09 | |
| dc.description.abstract | Objective: This study assessed trends in days’ supply for opioid prescriptions filled by adolescents with commercial insurance and Medicaid. Methods: IBM MarketScan commercial and Medicaid pharmacy claims data were used to measure days’ supply among adolescents (2005–2016) and to determine whether there were differences between patients with commercial insurance or Medicaid coverage. Results: The 2–3 days’ supply decreased from 50.5% (2005) to 36.7% of fills (2016), while 4–5 days’ supply increased from 30.2% to 37.7%. Fills of 6–7 and 8–15 days increased slightly. Fills of over 30 days remained near 0.0%, and one-day fills remained at 1.0–2.0% until 2016, when they increased to 3.6% Conclusions: For adolescents, fills of prescription opioids generally exceeded three days. Efforts to reduce opioid prescribing through guidelines, prescription drug monitoring programs, and limits on days’ supply do not appear to have affected prescribing for adolescents as much as desired. | en_US |
| dc.description.sponsorship | This work was supported by SAMHSA HHSS283201200031I/Task Order HHSS28342002T | en_US |
| dc.description.uri | https://ps.psychiatryonline.org/doi/10.1176/appi.ps.201700562 | en_US |
| dc.format.extent | 4 pages | en_US |
| dc.genre | journal articles | en_US |
| dc.identifier | doi:10.13016/m2zpew-apsc | |
| dc.identifier.citation | Henke, Rachel Mosher et al.; Opioid Prescribing to Adolescents in the United States From 2005 to 2016; Psychiatric Services, 69, 9, p 1040-1043, 9 July, 2018; https://doi.org/10.1176/appi.ps.201700562 | en_US |
| dc.identifier.uri | https://doi.org/10.1176/appi.ps.201700562 | |
| dc.identifier.uri | http://hdl.handle.net/11603/21895 | |
| dc.language.iso | en_US | en_US |
| dc.publisher | American Psychiatric Association | en_US |
| dc.relation.isAvailableAt | The University of Maryland, Baltimore County (UMBC) | |
| dc.relation.ispartof | UMBC School of Public Policy Collection | |
| dc.rights | This item is likely protected under Title 17 of the U.S. Copyright Law. Unless on a Creative Commons license, for uses protected by Copyright Law, contact the copyright holder or the author. | |
| dc.rights | Public Domain Mark 1.0 | * |
| dc.rights | This work was written as part of one of the author's official duties as an Employee of the United States Government and is therefore a work of the United States Government. In accordance with 17 U.S.C. 105, no copyright protection is available for such works under U.S. Law. | |
| dc.rights.uri | http://creativecommons.org/publicdomain/mark/1.0/ | * |
| dc.title | Opioid Prescribing to Adolescents in the United States From 2005 to 2016 | en_US |
| dc.type | Text | en_US |